$0.38
Value $12M
EHTH and JPM stock compared: price, dividend, valuation and results, from SEC filings.
$0.38
Value $12M
$338.25
Value $912B
eHealth (EHTH) has a market value of $12M and JP Morgan Chase & Co. (JPM) $912B. Over the last year, with dividends, EHTH moved -90.0% and JPM +13.5%. Dividend yield: EHTH none, JPM 1.82%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EHTH$12M
JPM$912B
JPM is 76,936 times EHTH
Revenue, 12 months
EHTH$469M
JPM$203B
JPM is 433 times EHTH
Net income, 12 months
EHTH$23M
JPM$66.0B
JPM is 2,874 times EHTH
Operating margin
EHTH10.6%
JPM–
ROIC
EHTH4.9%
JPM15.1%
10.2 points apart
P/E
EHTH–
JPM14.1
Dividend yield
EHTH0.0%
JPM1.8%
1.8 points apart
5-year return
EHTH-98.6%
JPM+129.9%
228.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EHTH-98.6%
JPM+129.9%
| Period | EHTHWith dividends | JPMWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -90.0%Price -90.0% | +13.5%Price +11.4% |
| 3 years since November 16, 2023 | -95.0%-63.2% a yearPrice -95.0% | +138.0%+33.5% a yearPrice +123.3% |
| 5 years since November 15, 2021 | -98.6%-57.5% a yearPrice -98.6% | +129.9%+18.1% a yearPrice +103.0% |
| 10 years since November 16, 2016 | -96.1%-27.8% a yearPrice -96.1% | +467.0%+18.9% a yearPrice +336.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EHTHeHealthJPMJP Morgan Chase & Co.
| Price | $0.38 | $338.25 |
|---|---|---|
| Market value | $12M | $912B |
| Enterprise value (EV) | – | – |
| P/E | – | 14.1 |
| P/E, 5-year median | – | 11.1 |
| P/B | 0.0 | 2.6 |
| EV/EBIT | – | – |
| Free cash flow yield | – | – |
| Revenue, 12 months | $469M | $203B |
|---|---|---|
| Net income, 12 months | $23M | $66.0B |
| Free cash flow, 12 months | -$17M | – |
| Earnings per share, 12 months | -$0.89 | $23.85 |
| Revenue growth, year on year | 4.1% | 2.8% |
| Revenue growth a year, past | -1.0%over 5 years | +8.8%over 5 years |
| EPS growth a year, past | – | +17.7%over 5 years |
| Gross margin | 44.7% | – |
|---|---|---|
| Operating margin | 10.6% | – |
| Net margin | 4.9% | 32.5% |
| ROIC | 4.9% | 15.1% |
| ROE | 4.2% | 18.0% |
| Cash | $88M | $1.11T |
|---|---|---|
| Total debt | – | $531B |
| Net debt / EBITDA | – | – |
| Interest cover | 3.2× | – |
| Dividend yield | – | 1.8% |
|---|---|---|
| Dividend per share, 12 months | – | $6.15 |
| Dividend growth a year, past | – | +10.0%over 5 years |
| Buyback yield | – | 3.5% |
| Shareholder yield | – | 5.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, JP Morgan Chase & Co. ($912B) is about 76,936.5 times eHealth ($12M), at today's prices.
Since November 16, 2016, EHTH's price moved -96.1% and JPM's +336.9%. With dividends: EHTH -96.1% (-27.8% a year), JPM +467.0% (+18.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for eHealth and 1.82% for JP Morgan Chase & Co.. Over the last twelve months they paid – and $6.15 per share.
Over the last twelve months, the net margin was 4.9% for eHealth and 32.5% for JP Morgan Chase & Co., and the operating margin 10.6% and –. Revenue was $469M and $203B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.